|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
Address correspondence and reprint requests to Dr. Marinos C. Dalakas, Neuromuscular Diseases Section, NINDS, NIH, Building 10, Room 4N248, 10 Center Dr., MSC 1382, Bethesda, MD 20892-1382; e-mail: dalakasm{at}ninds.nih.gov
Muscle biopsies from patients with sporadic inclusion-body myositis (sIBM) consistently demonstrate that the inflammatory T cells almost invariably invade intact (not vacuolated) fibers, whereas the vacuolated fibers are rarely invaded by T cells. This indicates two concurrently ongoing processes, an autoimmune mediated by cytotoxic T cells and a degenerative manifested by the vacuolated muscle fibers and deposits of amyloid-related proteins. The autoimmune features of IBM are highlighted by the strong association of the disease with: a) HLA I, II antigens, in frequency identical to classic autoimmune diseases; b) other autoimmune disorders in up to 32% of the patients, autoantibodies, paraproteinemias, or immunodeficiency; c) HIV and HTLV-I infection with increasingly recognized frequency (up to 13 known cases); and d) antigen-specific, cytotoxic, and clonally expanded CD8+ autoinvasive T cells with rearranged T-cell receptor genes that persist over time, even in different muscles, and invade muscle fibers expressing MHC-I antigen and costimulatory molecules. In contrast to IBM, in various dystrophies the inflammatory cells are clonally diverse and the muscle fibers do not express MHC-I or costimulatory molecules in the pattern seen in IBM. Like other chronic autoimmune conditions with coexisting inflammatory and degenerative features (i.e., primary progressive MS), IBM is resistant to conventional immunotherapies. Recent data suggest that strong anti-T cell therapies can be promising and they are the focus of ongoing research.
This article was previously published in electronic format as an Expedited E-Pub at www.neurology.org.
Disclosure: The author reports no conflicts of interest.
Received June 22, 2005. Accepted in final form October 14, 2005.
This article has been cited by other articles:
![]() |
M. Kitazawa, V. Vasilevko, D. H. Cribbs, and F. M. LaFerla Immunization with Amyloid-{beta} Attenuates Inclusion Body Myositis-Like Myopathology and Motor Impairment in a Transgenic Mouse Model J. Neurosci., May 13, 2009; 29(19): 6132 - 6141. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Schmidt and M. C. Dalakas Inflammation interrelates to APP in sIBM: IL-1{beta} induces accumulation of {beta}-amyloid Brain, April 1, 2009; 132(4): e107 - e107. [Full Text] [PDF] |
||||
![]() |
S. A. Greenberg Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications Neurology, November 20, 2007; 69(21): 2008 - 2019. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Finch A perspective on sporadic inclusion-body myositis: The role of aging and inflammatory processes Neurology, January 24, 2006; 66(1_suppl_1): S1 - S6. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. K. Engel and V. Askanas Inclusion-body myositis: Clinical, diagnostic, and pathologic aspects Neurology, January 24, 2006; 66(1_suppl_1): S20 - S29. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |